Company intelligence / Profile preview
Calm Water Therapeutics
New York, United Statesipqwery.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company has completed two proof-of-concept clinical studies of PEGPLUS-containing eye drops in dry eye disease. The product was safe and well-tolerated, with favorable results versus standard of care comparator in both studies and improved signs and symptoms in chronic dry eye patients.
- Therapeutic areas
- Ophthalmology
- Modalities
- Polymer-based therapeuticsProprietary polymers
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Calm Water Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Calm Water Therapeutics.